Contrafect Corp (CFRX)

[420man]

Anyone able to verify as to why this dropped so hard today when the PR indicated positive endpoint results? TIA

[420man]

I'm curious.. How do you buy at an avg. of 1.14 and then flip for a couple grand when it never went back above that PPS the entire day?

[Dream_Weaving]

OMG looked back here, I LOVE IT when I slap a turd like this make a couple grand and come back to see it DUMP!


I'll check back here a couple days to see for another flipper.

[Dream_Weaving]

I LOVE making a fast 10%, quick couple grand on da flipper!!!

[willlbone]

Bids under a buck.

[Dream_Weaving]

Grabbed me a block at 1.14 average for da flippa!

[willlbone]

Nice flop today.

[noretreat]

nice flips here lately

[ClayTrader]

* * $CFRX Video Chart 12-04-18 * *

Link to Video - click here to watch the technical chart video

[noretreat]

that is where I have been slowly accumulating for several years

ready for the breakout...

[umiak]

Last 8k: “Over the past quarter, we presented scientific data from a series of studies that continue to provide us with confidence in the potency and activity profile of our lead lysin product candidate, CF-301 (exebacase) and the potential of our broader lysin platform,”

[umiak]

Technical lows usually prove to be good buying territory.

[noretreat]

buy signal today...getting close to RSI of 30.

[noretreat]

Lots of institutions own this...

ConFect Corp,rp, Inst Holders, 2Q 2018 (CFRX)
DOW JONES & COMPANY, INC. 2:10 AM ET 7/19/2018
The following table shows the largest shareholders in CONTRAFECT CORP COM (CFRX) for the quarter ended June 30, 2018, listed by holding size. The list represents up to 50 of the largest holders in the company.

Note: Unless otherwise mentioned the reporting date is 06/30/2018

Institution Shares Shares % Last
Held Changed Held Report


Baker Bros. Advisors LP 7,153,076 0 9.711 03/31
Federated Global Investment Ma 6,000,000 0 8.146 03/31
Adage Capital Management LP 4,100,000 0 5.566 03/31
BVF Partners LP 3,500,000 0 4.752 03/31
Cormorant Asset Management LP 3,392,234 (157,766) 4.605 03/31
Oracle Investment Management 3,167,013 266,596 4.300 03/31
683 Capital Management LLC 2,500,000 (117,004) 3.394 03/31
The Vanguard Group Inc. 2,041,381 522,831 2.771 03/31
Birchview Capital LP 1,135,082 0 1.541 03/31
Broadfin Capital LLC 389,475 (842,191) 0.529 03/31
Geode Capital Management LLC 311,407 0 0.423 03/31
White Pine Capital LLC 186,655 (3,450) 0.253 03/31
BlackRock Fund Advisors 157,448 601 0.214 03/31
Renaissance Technologies LLC 142,600 (51,900) 0.194 03/31
DRW Securities LLC 110,000 30,000 0.149 03/31
JPMorgan Securities LLC (Inves 82,528 82,528 0.112 03/31
Opus Point Partners Management 75,000 (75,000) 0.102 03/31
PanAgora Asset Management Inc 63,954 0 0.087 03/31
Acadian Asset Management LLC 49,946 49,946 0.068 03/31
The Bank of New York Mellon Co 47,907 47,907 0.065 03/31
Morgan Stanley Smith Barney LL 44,631 41,881 0.061 03/31
Northern Trust Investments In 42,612 25,130 0.058 03/31
Goldman Sachs & Co. LLC (Priva 37,682 37,682 0.051 03/31
Virtu Financial BD LLC 37,304 (30,476) 0.051 03/31
Trellus Management Co. LLC 30,118 30,118 0.041 03/31
J.M. Hartwell LP 30,000 30,000 0.041 06/30
SSgA Funds Management Inc. 27,300 27,300 0.037 03/31
Loeb Partners Corp. 25,725 0 0.035 03/31
Brown Advisory LLC 25,000 0 0.034 03/31
BlueCrest Capital Management ( 24,185 24,185 0.033 03/31
Jefferies Investment Advisers 23,300 23,300 0.032 03/31
Rockefeller & Co. LLC 18,736 18,736 0.025 03/31
Rockefeller & Co. Inc. 18,736 18,736 0.025 03/31
Citadel Advisors LLC 17,702 17,702 0.024 03/31
Ardsley Advisory Partners 15,000 0 0.020 03/31
Klingenstein Fields & Co. LLC 15,000 0 0.020 03/31
Vanguard Fiduciary Trust Co. 13,286 (10,318) 0.018 03/31
BlackRock Investment Managemen 12,210 0 0.017 03/31
Merrill Lynch Pierce Fenner 11,425 4,375 0.016 03/31
AMG National Trust Bank 10,000 0 0.014 03/31
PNC Bank NA (Investment Manag 6,000 0 0.008 03/31
UBS Securities LLC 5,301 4,498 0.007 03/31
UBS Financial Services Inc. 4,800 0 0.007 03/31
Carroll Financial Associates 2,000 0 0.003 03/31
Benjamin F. Edwards & Co. Inc 1,000 0 0.001 03/31
Barclays Capital Inc. 2 2 0.000 03/31
Millennium Management LLC 0 (60,617) 0.000 03/31
RBC Dominion Securities Inc. 0 (7) 0.000 03/31
Deutsche Asset Management Inve 0 (116,224) 0.000 03/31
Thompson Davis & Co. Inc. (In 0 (33,000) 0.000 03/31

[SweatpantKing]

Wish I bought more at $1! Probably can still make some money at this price.

[Janko1]

Could make a run for a double from here.

[noretreat]

here comes contrafect....

[umiak]

Nice!

[umiak]

$1.80 held for now, yay! Anybody read/write Korean? lol

[Janko1]

It will be...

[ronpopeil]

This is a very exciting message board

[ronpopeil]

Any thoughts on CFRX. Seems to have an exciting program for handling superbugs. Could be a new paradigm in treating deadly viruses. Very strong institutional ownership for such a small company

[Janko1]

Good little Biotech to tuck away in your IRA....

[noretreat]

yes. i pulled the plug about halfway back. hope i don't miss an announcement

[$5.95akadawson-m]

one helluva head-fake

[noretreat]

rolling into good news here.

up over 100% now

[noretreat]

no idea. fidelity is okay...takes a while though. nice run up to end the day.

[$5.95akadawson-m]

can't buy shares at market price. what's up with that? through schwab.

[noretreat]

on a nice uptrend

[noretreat]

Up 20% last couple weeks.

[noretreat]

Buy this and hold it.

ContraFect Corp, Inst Holders, 4Q 2017 (CFRX)
DOW JONES & COMPANY, INC. 2:10 AM ET 1/19/2018
The following table shows the largest shareholders in CONTRAFECT CORP COM (CFRX) for the quarter ended December 31, 2017, listed by holding size. The list represents up to 50 of the largest holders in the company.

Note: Unless otherwise mentioned the reporting date is 12/31/2017

Institution Shares Shares % Last
Held Changed Held Report


Baker Bros. Advisors LP 7,153,076 3,107,200 9.711 09/30
Federated Global Investment Ma 6,000,000 4,000,000 8.146 09/30
Adage Capital Management LP 4,100,000 1,600,000 5.566 09/30
Cormorant Asset Management LLC 3,550,000 0 4.820 09/30
BVF Partners LP 3,500,000 3,500,000 4.752 09/30
Broadfin Capital LLC 2,711,561 1,386,205 3.681 09/30
683 Capital Management LLC 2,600,000 2,600,000 3.530 09/30
Oracle Investment Management 2,182,032 1,000,000 2.962 09/30
The Vanguard Group Inc. 1,469,247 491,110 1.995 09/30
Alyeska Investment Group LP 1,410,273 721,229 1.915 09/30
Birchview Capital LP 1,135,082 410,000 1.541 09/30
Geode Capital Management LLC 311,407 243,138 0.423 09/30
White Pine Capital LLC 290,330 36,460 0.394 09/30
Westfield Capital Management C 150,700 1,100 0.205 09/30
Millennium Management LLC 150,463 90,401 0.204 09/30
Opus Point Partners Management 150,000 0 0.204 09/30
BlackRock Fund Advisors 142,004 48,363 0.193 09/30
Sabby Capital LLC 119,156 119,156 0.162 09/30
Renaissance Technologies LLC 75,800 75,800 0.103 09/30
Goldman Sachs & Co. LLC (Priva 47,771 (17,502) 0.065 09/30
Deutsche Asset Management Inve 43,492 43,492 0.059 09/30
Virtu Financial BD LLC 33,283 33,283 0.045 09/30
Loeb Partners Corp. 25,725 0 0.035 09/30
Brown Advisory LLC 25,000 0 0.034 09/30
Rockefeller & Co. Inc. 18,736 (1,515) 0.025 09/30
Northern Trust Investments In 17,482 0 0.024 09/30
PanAgora Asset Management Inc 17,202 7,751 0.023 09/30
Klingenstein Fields & Co. LLC 15,000 0 0.020 09/30
Citadel Advisors LLC 13,263 13,263 0.018 09/30
BlackRock Investment Managemen 12,210 5,659 0.017 09/30
AMG National Trust Bank 10,000 0 0.014 09/30
PNC Bank NA (Investment Manag 6,000 0 0.008 09/30
IFP Advisors Inc. 6,000 0 0.008 09/30
UBS Financial Services Inc. 4,800 0 0.007 09/30
Vanguard Fiduciary Trust Co. 3,700 0 0.005 09/30
Morgan Stanley Smith Barney LL 2,550 1,000 0.003 09/30
Merrill Lynch Pierce Fenner 2,050 0 0.003 09/30
Carroll Financial Associates 2,000 2,000 0.003 09/30
Benjamin F. Edwards & Co. Inc 1,000 0 0.001 12/31
Morgan Stanley & Co. LLC 318 290 0.000 09/30
UBS Securities LLC 0 (4,805) 0.000 09/30
RBC Dominion Securities Inc. 0 (6) 0.000 09/30
Tower Research Capital LLC 0 (2,934) 0.000 09/30
Wells Fargo Clearing Services 0 (7,500) 0.000 09/30
Alpha Omega Wealth Management 0 (750) 0.000 09/30

13F data provided by: Factset Research Systems Inc.;
Please send questions to [e-mail].
Copyright, Factset Research Systems, 2018. All Rights Reserved.


(END) Dow Jones Newswires
01-19-180310ET

[terragord7]

amazing baker here, Rockefeller university an investor, 68% controlled by institutionals and nobody follows here

[Rolling inflaton]

Only potential problem with this drug is that it is too effective, kills too many bacteria immediately and bacteria debris can produce a cytokine storm. But management is well aware and designed the trial with this in mind: low dose in combination with SOC, it is only a matter of finding the optimal dose. Going to be a qualitative jump in antibiotic efficacy and likely to get accelerated approval if they got the dose right.

[noretreat]

And here is thing number 2> (which means NOW a good time to take a position)

ContraFect Seeks to Raise $40 Mln in Underwritten Public Offering of Shares, Warrants
MIDNIGHT TRADER 8:32 AM ET 7/20/2017

09:32 AM EDT, 07/20/2017 (MT Newswires) -- ContraFect(CFRX) , a biotechnology company, said on Thursday it aims to raise $40 million from an underwritten public offering of shares and warrants, which it priced at $1.25 per share and warrant.

The company is selling 32 million shares of its common stock and related warrants, which enable the holder to buy 16 million shares with an exercise price of $1.55 per share.

The offering is expected to close on or about July 25.

Piper Jaffray is the sole book-running manager and William Blair & Co. is the lead manager.

The shares lost nearly 14% shortly after the market's open Thursday.

Price: 1.25, Change: -0.20, Percent Change: -13.79

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

[noretreat]

A couple of things about this stock

Here is thing number 1> (Judge for yourself)

ContraFect Corp, Inst Holders, 2Q 2017 (CFRX)
DOW JONES & COMPANY, INC. 2:11 AM ET 7/19/2017
The following table shows the largest shareholders in CONTRAFECT CORP COM (CFRX) for the quarter ended June 30, 2017, listed by holding size. The list represents up to 50 of the largest holders in the company.

Note: Unless otherwise mentioned the reporting date is 06/30/2017

Institution Shares Shares % Last
Held Changed Held Report


Baker Bros. Advisors LP 4,045,876 0 9.713 03/31
Cormorant Asset Management LLC 3,550,000 (292,966) 8.522 03/31
Adage Capital Management LP 2,500,000 0 6.002 03/31
Federated Global Investment Ma 2,000,000 0 4.801 03/31
Broadfin Capital LLC 1,429,109 0 3.431 03/31
Oracle Investment Management 1,182,032 0 2.838 03/31
The Vanguard Group Inc. 1,019,332 0 2.447 03/31
Birchview Capital LP 725,082 0 1.741 03/31
Alyeska Investment Group LP 712,614 (71,023) 1.711 03/31
Opus Point Partners Management 300,000 0 0.720 03/31
White Pine Capital LLC 253,045 (23,850) 0.607 03/31
Sunbelt Securities Inc. 200,000 0 0.480 03/31
Westfield Capital Management C 149,600 149,600 0.359 03/31
Goldman Sachs & Co. LLC (Priva 103,098 (95,359) 0.247 03/31
BlackRock Fund Advisors 90,998 0 0.218 03/31
Millennium Management LLC 78,225 (17,957) 0.188 03/31
Geode Capital Management LLC 71,850 486 0.172 03/31
Loeb Partners Corp. 25,725 0 0.062 03/31
Brown Advisory LLC 25,000 0 0.060 03/31
The Bank of New York Mellon Co 21,141 21,141 0.051 03/31
Rockefeller & Co. Inc. 20,251 3,297 0.049 03/31
Northern Trust Investments In 17,482 17,482 0.042 03/31
Klingenstein Fields & Co. LLC 15,000 0 0.036 03/31
AMG National Trust Bank 10,000 10,000 0.024 03/31
LPL Financial LLC 10,000 (9,260) 0.024 06/30

[noretreat]

here's something...not about the warrants, but....stock is down today because of the offering. May be a good place to add.

Every year the biotech showcase is an excellent chance to discover investment opportunities and to conduct due diligence. This year's showcase was no exception, even though the near term share price outlook seems bleak for biotech in general. Many of the companies I'm going to mention have already seen 50% share price drops. Some much more than that. As I write this today (January 20), the IBB index is at 276, off from its 52-week high of 400 last July.

In my view, current conditions are an opportunity. "Babies are being thrown out with the bathwater". Here are some examples.

----etc----

Contrafect

Another interesting anti-infective company is Contrafect. Their lead product, CF-301, may work better than current treatments against some of the worst infections, including staph bacteremia. In combination with Daptomycin and Vancomycin there appears to be a significant increase in efficacy and limited additional side effects.

Contrafect has a number of other products, including a promising drug cocktail combining 3 monoclonal antibodies for many strains of influenza.

The stock is trading a bit over $4 right now, down from $6.24 last April. The company raised $20 million in a private placement last June, and announced a $30 million ATM offering after the close today. There is plenty of funding here.

-----etc-----

[maokin]

Newbie, here: Any thoughts on the viability of the warrants CFRXW (exp: 01/31/2017 currently selling at $1.44)?

MANY TIA.

[mantisforce]

I am back in, and hoping for a great 2016!

[WolfWayne]

Merry Christmas!

[stocktrademan]

$CFRX recent news/filings

bullish 4.90
not making lower highs lower lows downtrend anymore
crossed moving averages up and seems to find support on them now
markets can change and posts are usually not updated
weekly chart shows large bullish engulfing candle
high green volume

## source: finance.yahoo.com

Wed, 16 Dec 2015 21:30:00 GMT ~ CFRX: Phase 1 Study of CF-301 Complete with No Clinical Adverse Safety Signals Found; Increasing PT to $12


read full: http://finance.yahoo.com/news/cfrx-phase-1-study-cf-213000740.html
*********************************************************

Tue, 15 Dec 2015 12:16:11 GMT ~ ContraFect Corporation Concludes Phase 1 Study of CF-301

[at noodls] - -- () -- -- (NASDAQ: CFRX)(NASDAQ: CFRXW), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant ...

read full: http://www.noodls.com/view/13079E27FA87714DE59312EF29C0F3699434B228
*********************************************************

Tue, 15 Dec 2015 12:00:00 GMT ~ ContraFect Corporation Concludes Phase 1 Study of CF-301

[Marketwired] - ContraFect Corporation , a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious......

read full: http://finance.yahoo.com/news/contrafect-corporation-concludes-phase-1-120000060.html
*********************************************************

Tue, 08 Dec 2015 18:17:47 GMT ~ CONTRAFECT CORP Financials


read full: http://finance.yahoo.com/q/is?s=cfrx
*********************************************************

Tue, 08 Dec 2015 08:55:00 GMT ~ Hedge Funds Are Betting On ContraFect Corp (CFRX)


read full: http://www.insidermonkey.com/blog/hedge-funds-are-betting-on-contrafect-corp-cfrx-400715/
*********************************************************

$CFRX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CFRX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CFRX/company-info
Ticker: $CFRX
OTC Market Place: Not Available
CIK code: not found
Company name: ContraFect Corporation
Incorporated In:


$CFRX share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$CFRX extra dd links

Company name: ContraFect Corporation
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CFRX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CFRX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CFRX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CFRX/news - http://finance.yahoo.com/q/h?s=CFRX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CFRX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CFRX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CFRX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CFRX
DTCC (dtcc.com): http://search2.dtcc.com/?q=ContraFect+Corporation&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=ContraFect+Corporation
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=ContraFect+Corporation&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CFRX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CFRX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CFRX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CFRX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CFRX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CFRX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CFRX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CFRX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CFRX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CFRX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CFRX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CFRX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CFRX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CFRX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CFRX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CFRX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CFRX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CFRX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CFRX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CFRX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CFRX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CFRX



$CFRX DD Notes ~ http://www.ddnotesmaker.com/CFRX

[WolfWayne]

Welcome!

[With28jumpersexecute]

I'm with you!

[WolfWayne]

Low volume, holding ground, great buying opportunity here. Further P1 news or news of P2 plans could come any day. When it does, this may run to $7 or $8.

[WolfWayne]

"ContraFect also has several advantages working in its favor. In March 2015, the White House released the National Action Plan for Combating Antibiotic-Resistant Bacteria, where the President laid out 5 goals to developing new antibiotic drugs and specifically pointed to supporting phage-derived lysins to kill specific bacteria. This is significant because it shows government support for an area where ContraFect is currently the only company allowed by the FDA to conduct a phage-derived lysin program. In addition, the FDA granted fast track designation to CF-301, adding another catalyst to the program."

[WolfWayne]

ContraFect Is A Speculative Buy On Positive News From Phase 1 Trials $CFRX
http://www.seekingalpha.com/article/3762106

[WolfWayne]

$CFRX "Drug-resistant and newly emerging pathogens are responsible for hospital-based infections, the FOURTH leading cause of death in US"

[WolfWayne]

[WolfWayne]

Busted $5!

[WolfWayne]

MMs defending 5.00 like yesterday's defense of 4.00. If this breaks 5.00, and I think it will, ask is looking thin to 6.00 :)

[WolfWayne]

Last day under $5?